miR-21 Expression and its Correlation with Demographics, Subtypes, and Tumour Suppressor Genes; PTEN and PDCD4 in Breast Cancer Tissues in Malaysia

Sharon Rachel Wong,1 Chong Pei Pei,1,5 Mohd Tamrin Mohd Isahuddin,2 Anita Baghawi,3 Gew Lai Ti,4 Nallammai Singaram,1 Lee Sau Har1,5

1School of Biosciences, Faculty of Health and Medical Sciences, Taylor’s University, Selangor, Malaysia
2Surgical Department, Faculty of Medicine and Health Sciences, University Putra Malaysia (UPM), Serdang, Selangor, Malaysia
3Department of Breast and Endocrine Surgery, Hospital Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia
4Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Selangor, Malaysia
5Digital Health and Medical Advancements Impact Lab, Taylor’s University, Selangor, Malaysia

Abstract

Objectives: Despite extensive research in breast cancer (BC) genomics, most studies are from Western countries, which do not reflect the multi-ethnic make-up of Malaysia. Hence, microribonucleic acid-21 (miRNA-21), which is known to be an oncogenic stimulator of BC will be investigated by comparing its expression between breast tumour tissues and normal adjacent tissues excised from 67 BC patients, ethnic groups, age groups distribution, neo-adjuvant chemotherapy (NAC) treated and untreated patients, as well as BC subtypes.

Methods: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to measure the distribution of miR-21 expression in the paired BC tissues. The expression of the tumour suppressors; PTEN and PDCD4 was also investigated via RT-qPCR and Western Blot for its gene and protein expressions.

Results: The results only showed the significance of miR-21 and PTEN expression between the normal adjacent tissues and BC tissues (p<0.05). Additionally, there was a lack of correlation between gene expression of miR-21 against PTEN and PDCD4. Protein expression analysis did not show a significant difference in tumour suppressor proteins; PTEN and PDCD4 expression in both tissue types.

Conclusion: miR-21 has a notable presence in BC and is a suitable biomarker to be evaluated further in patients of all ethnicities and age groups.

Keywords: Breast cancer, Malaysia, miR-21, PTEN, PDCD4.


Breast cancer (BC) is a complex disease that poses a significant challenge to human health, quality of life, and financial burden, both in Malaysia, and worldwide.[1] The International Agency for Research on Cancer’s GLOBOCAN statistical analysis reveals that the BC mortality rate has reached 8,418 new cases among Malaysia’s female popula-
tion of all ages, with a total of 29,453 cases within a 5-year prevalence span. Additionally, a joint study between two tertiary academic hospitals in Malaysia and Singapore concluded that 50% of women in their sample group were diagnosed before the age of 50 years. Meanwhile in Western countries, 20% are diagnosed before age 50. This is supported by data that reveals the mean age of BC presentation in Malaysia is 26.1 years, compared to 39.8 years of age in the United Kingdom. Ethnicity is a key risk factor for one's lifetime risk of developing BC. In Malaysia, BC risk is highest among the Chinese population, followed by Indians, then Malays. Thus, the genetic underpinning differences of BC risk in different ethnicities and age groups are poorly understood.

Breast tissue is highly heterogeneous, and is composed of breast stem cells, myoepithelial cells, epithelial cells, and glandular cells. BC is similarly heterogeneous, as neoplastic changes may occur in any of these cell types. BC can be classified into subtypes depending on the presence or absence of receptors expressed by cancerous cells. These receptors include oestrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor 2 (HER2). BC subtypes include Luminal A (ER-positive, PR-positive, HER2-negative), which accounts for 50-60% of BCs, and is associated with good prognosis. Luminal B (ER-positive, PR-negative, HER2-positive or negative) accounts for 15-20% of BCs, characterised as a more aggressive phenotype, and is associated with poorer prognosis. Triple negative BCs (TNBC) (negative for ER, PR, and HER2), accounts for 12-17% of BCs, have high recurrence rates, and poorer prognosis. TNBC's behaviour is relatively aggressive compared to other subtypes and have characteristic metastatic patterns. Lastly, HER2-positive BC (ER & PR-negative, HER2-positive) accounts for 15-20% of BC cases. HER2 positivity is associated with more aggressive and invasive cellular behaviour but has a remarkably better prognosis due to the availability of effective targeted treatment. There are, however, no known biomarkers that provide prognostic information in any of the above BC subtypes. The identification of BC biomarkers that provide insights into disease progression and outcome may have important clinical value to medical practitioners and patients alike.

The primary methods of treating BC include surgical excision, radiotherapy, and chemotherapy. All three modalities may be used in a number of different combinations depending on tumour grade (aggressiveness) and staging (degree of spread). A general approach typically utilises a course of neoadjuvant (or pre-treatment) chemotherapy to reduce tumour size, followed by surgical excision of the tumour, and then adjuvant (post-treatment) chemotherapy or radiotherapy to minimise remaining microscopic, undetectable cancer cells. The usage of neoadjuvant therapy is associated with lower rates of BC recurrence and mortality. Despite the promising outcomes of NAC in BC, the effect of its administration against oncogenic miRNAs is unknown.

The main post-transcriptional regulators of gene expression in different tissues and developmental stages are miRNAs. They accomplish this through highly specific interactions and complex regulatory networks. miRNAs can be divided into oncogenic miRNAs (oncomiRs) and tumour suppressor miRNAs (tsmiRs). OncomiRs are typically upregulated in BC, while tsmiRs prevent cancer initiation through modulating oncoproteins that code for gene expression. The oncomiR of interest in this study is miR-21, a key oncomiR in many cancer subtypes, and whose expression is dramatically up-regulated in BC. miR-21 targets and inhibits the activity of programmed cell death 4 (PDCD4) and phosphatase and tensin homolog (PTEN), both of which are tumour suppressor genes. This is supported by evidence that associates the downregulation of PTEN and PDCD4 with poor prognosis in BC. However, studies that aim to establish a link between miR-21 overexpression with PTEN and PDCD4 expression have yielded mixed results with some studies exhibiting an expected negative correlation while others exhibited negligible correlation.

In BC, the overexpression of miR-21 is significantly correlated with advanced clinical staging, lymph node metastasis, and poor prognosis. The over-expression of miR-21 in BC has potential clinical implications that require further investigation. Additionally, its association with more advanced disease may make it an important biomarker to monitor for disease progression and inform prognostication. To validate its use, further investigation should attempt to quantify its expression among different ethnic populations, given that BC incidence and prevalence is known to vary between ethnicities. Therefore, the question persists if miR-21 gene expression levels differ in different ethnic groups. That being said, the vast majority of the existing evidence regarding miR-21 expression has been performed with populations of homogenous ethnicities, e.g. Caucasian North Americans, or Han Chinese, or Indians. Further, attempts to compare miR-21 expression between these studies may be confounded by the variable access to cancer therapies and quality of the therapies between these countries. Malaysia offers a multi-ethnic population that is exposed to a standardised approach to cancer care, and comparable quality of said care between patients, thus making it a promising location for a comparative multi-ethnic study comparing miR-21 expression. Additional investigations must also be conducted to further elucidate the proposed correlation between miR-21 overexpression, and PTEN and PDCD4 expression.
downregulation. This study aims to investigate differential expression of miR-21 in BC cases among Chinese, Indian, and ethnic Malays in Malaysia, across different age groups, subtypes, treatment status, while concurrently investigating the association between miR-21 overexpression with PTEN and PDCD4 downregulation.

Methods

Ethical Considerations

This present study involves the use of human subjects which include tissue specimens. Therefore, human ethics approval has been applied and obtained for this project to collect the patients derived tissue specimens via the University Putra Malaysia institutional ethics review board and Ministry of Health Medical Research Ethics Committee (MREC) prior to the commencement of the study. The ethics approval code is NMRR-21-246-58614 (IIR). Clinical information was obtained from archived medical records. Informed patient consent were obtained.

Specimen Collection and Storage

Surgical mastectomies were excised by surgeons in Putrajaya Hospital. The nature and characterisation of both tissue specimens (breast tumour and normal adjacent tissue) were confirmed by the surgeon who has conducted mammograms and ultrasounds to locate the tumour and confirm the normal tissue. A segment of the excised tissues were then sent to the hospital’s histology specialists to confirm the normal tissue. A segment of the excised tissues were subsequently snap-frozen in liquid nitrogen for cryotanks and stored until RNA and protein extractions are performed (Loken and Demetrick, 2005, Zhang et al., 2019b, Zheng et al., 2019). Patient demographic data such as ethnicity, treatment prescription and clinical history was also collected from Hospital Putrajaya’s patient medical records to conduct demographical analysis based on this study’s results.

Inclusion and Exclusion Criteria

The inclusion criteria for this study consisted of Malaysian BC patients with informed consent, of any age and ethnicity, diagnosed with BC of any subtype, tumour size received has to be larger than 2 cm, patients who have undergone NAC treatment and treatment naïve patients. The exclusion criteria consisted of non-Malaysian BC patients and patients diagnosed with other chronic disease(s).

RNA Extraction

Tissue RNA extractions were carried out with a TRIzol® RNA extraction kit, following its user manual (Zymo Research, USA. Cat No: R2052). The eluted RNA was then measured for its concentration and quality using the UVisplate (BMG Labtech, Germany) and quantified using the NanoDrop quantification software. An acceptable reading of the 260/280 purity test should equate to a value above 1.8. After that, the extracted RNA samples were stored in -80°C until further use.

RT-qPCR Assay

The gene expression levels of miR-21, PTEN and PDCD4 were measured using RT-qPCR with their relative fold change expression calculated with the 2−ΔΔCT method. Primers used were: miR-21 forward primer: 5’-GCCGCTAGCTTTACAGACTGATG-3’, miR-21 reverse primer: 5’-CAGTGCAGGTCAGGATCC GAGGT-3’[46] U6 snRNA forward primer: 5’-TCCTCGCTTCGGCAACAA-3’, U6 snRNA reverse primer: 5’-AACGCTTCAGAATTGCGT-3’[47] PTEN forward primer: 5’-GACGAACTGGTGTGATATG-3’, PTEN reverse primer: 5’- GTGCCACTGTTCTATAATCC-3’,[48] PDCD4 forward primer: 5’- TCTGGGAAGAAGGGAGGACTAC-3’, PDCD4 reverse primer: 5’-GTCATACGGATGTCGCCAC-3’,[49] β-actin forward primer: 5’-GCACTGGTGTGATATG-3’ and β-actin reverse primer: 5’-GTGCCACTGTTCTATAATCC-3’,[48] U6 snRNA and β-actin were used as housekeeping genes for miRNA and mRNA detection, respectively. cDNA synthesis and RT-qPCR master mix for miR-21 detection purposes were prepared with GeneCopoeia’s All-in-One miRNA RT-qPCR Detection Kit 2.0 (GeneCopoeia Inc, USA. Cat No: QP115) for quantitative detection of mature miRNA while PTEN and PDCD4 cDNA synthesis was prepared with HiScript II 1st Strand cDNA Synthesis Kit (Vazyme Biotech, China. Cat No: R211) and the RT-qPCR master mix were prepared with ChamQ Universal SYBR® qPCR Master Mix (Vazyme Biotech, China. Cat No: Q711). RNA concentration of 10ng/µL was used to synthesise the respective cDNA. The reaction mix
was prepared according to the manufacturer’s protocol. Once cDNA synthesis was completed, cDNA concentration of 500ng/µL was used for RT-qPCR master mix preparation. The RT-qPCR master mix for miR-21, PTEN and PDCD4 gene expression analysis was performed following the manufacturer’s protocol. The prepared samples were placed into the real-time machine; CFX Opus 96 Real-Time PCR System (Bio Rad, USA). The RT-qPCR run setting for miR-21 gene expression consisted of a 3-step method; initial denaturation at 95°C for 10 minutes, then denaturation step at 95°C for 10 seconds, annealing step at 56°C for 20 seconds and finally the extension step at 72°C for 10 seconds. Meanwhile, the RT-qPCR run setting for PTEN and PDCD4 gene expression consisted of a 2-step method; initial denaturation at 95°C for 30 seconds, then denaturation step at 95°C for 10 seconds, annealing and extension step at 63°C for 30 seconds. The melting curve analysis for both sets of gene expression was performed based on the default conditions set by the instrument. In this study, the epithelial human breast cancer cell line, metastatic mammary adenocarcinoma1 (MDA-MB-231) is used as the reference sample for miR-21 RT-qPCR analysis due to its aggressive, invasive and poorly differentiated nature.\(^{50, 51}\) Meanwhile, the green African monkey kidney cell line (Vero), which resembles as a normal cell line is used as the reference sample for PTEN and PDCD4 RT-qPCR analysis.\(^{52, 53}\)

**Protein Extraction**

Tissue protein lysates were prepared based on the manufacturer’s protocol using Radiimmunoprecipitation Assay (RIPA) lysis buffer (Elabscience Biotechnology Inc, USA. Cat No: E-BC-R327). The protein concentration of samples was then measured with the bicinchoninic acid (BCA) assay (Elabscience Biotechnology Inc, USA. Cat No: E-BC-K318-M), adhering to manufacturer's protocol. The desired protein concentration used for all samples were standardised to 10µg. Following protein lysis standardisation, 10µL of 10µg samples were then mixed with an equal amount of SDS loading buffer (200mM, pH6.8 Tris-HCl, 8% (w/v) SDS, 0.4% bromphenol blue, 40% glycerol, add 100µL of β-mercaptoethanol per 900µL of whole volume), hence, producing a final volume of 20µL. The mixture was heated at 95°C for 5 minutes before proceeding with gel electrophoresis.

**Western Blot Protocol**

Reagents used for Western Blot protocols were prepared in house and methodology used was adapted from Zhang et al., (2021) and Liu et al., (2014). Sample proteins were resolved on sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (10% resolving gel and 4% stacking gel) in 1x electrolysis running buffer (1L: 250mM tris base, 192mM glycine and 10mL of 10% SDS) and the gel was run at 125V for 1 hour and 15 minutes. Filter papers and gel were soaked in 1x transfer buffer (1L: 25mM tris base, 192mM glycine, 20% (v/v) methanol) before proteins were semi-dry transferred onto polyvinylidene difluoride membrane (PVDF) (Millipore, USA. Cat No: R1JB27545) and was set at 20V for 1 hour to allow complete protein transfer. Once the transfer was done, the membrane was rinsed briefly in 1x tris buffered saline with tween-20 (TBST) (1L: 20mM tris, 150mM NaCl and 0.1% (w/v) Tween 20 detergent, pH adjusted to 7.6) and blocked with 5% Bovine Serum Albumin (BSA). Membranes were then incubated at 4°C overnight with primary antibodies: PTEN (SC-7974, Santa Cruz, USA), PDCD4 (SC-376430, Santa Cruz, USA) or β-actin (SC-47778, Santa Cruz, USA) which were diluted to working concentration of 1:1000 in 1x TBST. After washing steps with 1x TBST, the membrane was then incubated with diluted horse radish peroxidase (HRP) secondary antibody (sc-516102, Santa Cruz, USA) of a working solution of 1:10,000 for 1 hour in room temperature. The membrane was washed again with 1x TBST. The protein signals were then visualised with enhanced chemiluminescence (ECL) substrate (Elabscience Biotechnology, USA. Cat No: E-IR-R307). The membrane was incubated in the substrate for 1 minute and then exposed to autoradiography film in a dark setting and imaged with a chemiluminescent imaging system (Azure Biosystems A600, USA) (54, 55). The relative fold change of each protein expression were analysed by using Image J analysis software (National Institutes of Health, USA).

**Data Analysis**

The fold change (2^-ΔΔCT\;) of gene expression for miR-21, PTEN and PDCD4 were converted into the Log2 formula. The protein bands for western blot imaging was quantified with ImageJ software. After confirming the data obtained in this study is not normally distributed, non-parametric tests such as the Mann Whitney-U test was used to compare values across two groups such as PTEN and PDCD4 protein expression between the two tissue types and miR-21’s expression in NAC treated and untreated patients. The Kruskal-Wallis Test was also utilised to assess a relationship between miR-21 across different ethnicities, different subtypes and age groups of the patient cohort. Correlative statistics to deduce a correlation between gene expression of miR-21 against PTEN and PDCD4 was determined using the Spearman’s rho of correlation coefficient. All statistical tests were conducted using the statistical software; SPSS Statistics 27.0 (IBM, USA).
Results

Breast Cancer Cases in Hospital Putrajaya from Year 2020-2021

Demographic data collection for BC patients was conducted in Hospital Putrajaya, including age and ethnic groups, as per Table 2 to stratify BC incidence. The accumulated data was tabulated and presented (Fig. 1) to visualise the distribution of each demographic factor with BC incidence in years 2020-2021. Table 1, which represents the frequency of BC incidence, showed that the year 2020 had a total of 315 BC cases in Hospital Putrajaya. Meanwhile, the percentage of BC patients’ distribution among the age groups 25-40, 41-50, 51-64 and 65-86 were 15.6%, 23.5%, 38.1% and 22.9% cases, respectively, with a median age of 55 years old. Additionally, the distribution of ethnicity included 68.6% of Malay patients, 17.8% of Chinese ethnic, 12.1% Indian patients and 1.6% of patients categorised as ‘Others’. In the following year of 2021, a total number of 147 BC cases was recorded. The age groups distribution consisted 20.4% of patients in the 25-40 age group, 24.5% of patients in the 41-50 age group, 35.4% of patients in the 51-64 age group, and finally 19.7% patients in the 65-86 age group with a median age of 53 years old. Based on the ethnic groups, there were 79.6%

<table>
<thead>
<tr>
<th>Category</th>
<th>Year 2020 (n=315)</th>
<th>Percent (%)</th>
<th>Year 2021 (n=147)</th>
<th>Percent (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-40</td>
<td>49</td>
<td>15.6</td>
<td>30</td>
<td>20.4</td>
</tr>
<tr>
<td>41-50</td>
<td>74</td>
<td>23.5</td>
<td>36</td>
<td>24.5</td>
</tr>
<tr>
<td>51-64</td>
<td>120</td>
<td>38.1</td>
<td>52</td>
<td>35.4</td>
</tr>
<tr>
<td>65-86</td>
<td>72</td>
<td>22.9</td>
<td>29</td>
<td>19.7</td>
</tr>
<tr>
<td>Total</td>
<td>315</td>
<td>100</td>
<td>147</td>
<td>100</td>
</tr>
<tr>
<td>Median Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malay</td>
<td>216</td>
<td>68.6</td>
<td>117</td>
<td>79.6</td>
</tr>
<tr>
<td>Chinese</td>
<td>56</td>
<td>17.8</td>
<td>19</td>
<td>12.9</td>
</tr>
<tr>
<td>Indian</td>
<td>38</td>
<td>12.1</td>
<td>11</td>
<td>7.5</td>
</tr>
<tr>
<td>Others</td>
<td>5</td>
<td>1.6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>315</td>
<td>100</td>
<td>147</td>
<td>100</td>
</tr>
</tbody>
</table>

Table 2. Summary table of miR-21 expression and demographic variables of 67 breast cancer patients in Hospital Putrajaya

<table>
<thead>
<tr>
<th>Category</th>
<th>n=67</th>
<th>miR-21 Expression (mean±SD)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25-40</td>
<td>15</td>
<td>9.38±0.81</td>
<td>0.515</td>
</tr>
<tr>
<td>41-50</td>
<td>25</td>
<td>4.21±6.81</td>
<td></td>
</tr>
<tr>
<td>51-64</td>
<td>13</td>
<td>5.77±8.93</td>
<td></td>
</tr>
<tr>
<td>65-85</td>
<td>14</td>
<td>6.09±7.50</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malay</td>
<td>53</td>
<td>6.03±7.95</td>
<td>0.233</td>
</tr>
<tr>
<td>Chinese</td>
<td>7</td>
<td>9.25±9.92</td>
<td></td>
</tr>
<tr>
<td>Indian</td>
<td>7</td>
<td>3.09±8.17</td>
<td></td>
</tr>
<tr>
<td>Prescription</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neo-Adjuvant Chemotherapy</td>
<td>27</td>
<td>4.17±7.50</td>
<td>0.167</td>
</tr>
<tr>
<td>Untreated</td>
<td>40</td>
<td>7.34±8.45</td>
<td></td>
</tr>
<tr>
<td>Subtype</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luminal A</td>
<td>39</td>
<td>5.65±7.33</td>
<td>0.939</td>
</tr>
<tr>
<td>Luminal B</td>
<td>7</td>
<td>5.33±8.01</td>
<td></td>
</tr>
<tr>
<td>HER 2 Enriched</td>
<td>9</td>
<td>4.98±7.73</td>
<td></td>
</tr>
<tr>
<td>Triple Negative</td>
<td>12</td>
<td>8.66±11.30</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Bar chart of breast cancer cases in Hospital Putrajaya from (a) year 2020-2021, further segregated based on (b) ethnicity and (c) age group.
Malay patients, 12.9% Chinese patients and 7.5% Indian patients. The drastic decrease of BC patients admitted to Hospital Putrajaya between year 2020 to 2021 was because of a national lockdown during the novel COVID-19 outbreak. Not only that, but there was also a reduction of the operating theatre, therefore, only a selected number of cases can be performed on a weekly basis. Consequentially, a large quantity of BC patients were transferred to private hospitals to accommodate the influx of COVID-19 patients in Hospital Putrajaya.\textsuperscript{56} The total cases of BC in Hospital Putrajaya in years 2020 and 2021 were shown in Figure 1A to visualise the difference in frequency. Additionally, Figure 1B and Figure 1C are clustered bar graphs that represented the frequency of BC cases in Hospital Putrajaya based on ethnicity and age group in 2020 and 2021, respectively.

### miR-21 Expression in BC Patients among Malaysian Ethnic Groups

The analysis illustrated in Table 2 showed that the Chinese ethnicity exhibited the highest miR-21 expression despite having only 7 (10%) Chinese patients out of the total of 67 patients. This is followed by the Malay ethnicity with 53 (80%) patients, and finally the Indian ethnicity having the lowest expression among 7 (10%) patients. After conducting the Kruskal-Wallis test, no significance was found among the ethnic groups (p=0.233), based on miR-21 ex-

![Log2 bar charts of miR-21 expression among 67 breast cancer patients against (a) ethnicity, (b) age group, (c) neoadjuvant chemotherapy treated and non-neoadjuvant chemotherapy treated patients and (d) subtype, (e) miR-21, PTEN and PDCD4 against specimen type (breast tumour and normal adjacent tissue), (f) bar chart of protein expression of PTEN and PDCD4 of 67 breast cancer patients, (g) blot images of PTEN and PDCD4 protein expression for paired breast tumour tissues (T) and normal adjacent tissues (N) with protein fold expressions normalised with housekeeping protein: B-actin. The symbol '*' represents significant difference between variables (p<0.05).](image-url)
expression. The bar chart in Figure 2A showed the expres-
sional levels of miR-21 for each ethnic group.

**miR-21 Expression in BC Patients and its Association with Age Groups**

The expression levels of miR-21 were also measured among age groups. Based on Table 2, the patients were divided into four age groups to represent young, middle-age and se-
nior patients, namely 25-40 (younger age group) that con-
sisted of 15 patients (22%), 41-50 (early middle-age group) that consisted of 25 patients (38%), 51-64 (late middle-age group) that consisted of 13 patients (19%) and 65-85 (senior age group) consisted of 14 patients (21%) of the sample size. The results denoted no significance of miR-21 expression be-
tween the different age groups (p=0.515). However, miR-21 expression was found to be the highest among those in the 25-40 age group, followed by 65-85 age group, 41-50 and finally 51-64 age group. Figure 2B visualises the difference in miR-21 expression among all age groups.

**miR-21 Expression among Neo-Adjuvant Treated Patients and Untreated Patient Groups**

miR-21's expressional difference was also measured among BC patients who were treated with neo-adjuvant chemotherapy (27 patients, 40% of sample population) and patients who did not receive treatment (40 patients, 60% of sample population). Comparing miR-21 expres-
sion between patients who have undergone neoadjuvant treatment versus patients without prescribed treatment, showed no significant difference (p=0.167), as presented in Table 2. Figure 2C showed that the untreated patient group had a higher expression of miR-21 compared to the neo-
adjuvant treated group.

**miR-21 Gene Expression and Breast Cancer Subtypes**

In this study, the expression of miR-21 was investigated among the four main breast cancer subtypes. Among the 67 patients, luminal A consisted of 39 patients (58%), 7 (10%) luminal B patients, 9 (14%) HER-2 enriched patients, and 12 (18%) triple negative patients. The results in this section are presented in Table 2 that distinguished the differ-
et miR-21 expression among the four BC subtype groups with the respective number of patients in each group. Figure 2D aided in visualizing the different miR-21 expression for each patient group. However, no significant difference of miR-21’s expression among the four subtypes (p=0.939) was observed. Generally, triple negative subtype showed the highest miR-21 expression, followed by luminal B, luminal A and finally HER-2 enriched.

**Gene Expression of miR-21, PTEN and PDCD4 in Specimen Types**

Based on 67 paired tissue samples from breast cancer pa-
tients, Table 3 showed a significant difference between miR-21 (p<0.001) and PTEN (p=0.010) gene expression in both tissue types. The expressional difference between the paired tissues were tabulated as mean and standard deviation (STDEV). It showed that miR-21 expression is higher in the tumour specimen compared to its normal adjacent counterpart. Meanwhile PTEN showed a higher gene expression in the normal tissues compared to the tumour specimen. Finally, PDCD4 showed no expressional signifi-
cance between the tissue pair, p=0.451. However, PDCD4 was expressed higher in the normal tissues compared to the tumour specimens. These differential expressions can be observed in Figure 2E.

**Protein Expression of PTEN and PDCD4 in Tissues**

After conducting western blot procedure for 67 pairs of tis-
sues for protein detection and quantification of PTEN and PDCD4 (representative blots shown in Figure 2G), no sig-
nificant difference was found between the two tissue types and among both proteins (Table 3). When comparing the proteins expression however, Figure 2F, there was a slight increase of PTEN protein observed in the normal tissue

| Table 3. Genes and Proteins Expression Between Normal Adjacent Breast Tissues and Breast Cancer Tissues |
|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|------------------|
| **Gene Expression** | **Gene Expression of Normal Adjacent Tissue (mean±SD)** | **Gene Expression of Cancer Tissue (mean±SD)** | **p** |
| **Gene of Interest** | **n=67** | **Gene of Interest** | **n=67** | **Gene of Interest** | **n=67** | **Gene of Interest** | **n=67** | **Gene of Interest** | **n=67** | **Gene of Interest** | **n=67** | **Gene of Interest** | **n=67** |
| miR-21 | 67 | 1.42±8.09 | 6.06±8.18 | 0.000 |
| PTEN | 67 | 5.43±3.59 | 3.86±3.93 | 0.010 |
| PDCD4 | 67 | 0.92±5.10 | 0.02±4.72 | 0.451 |
| **Protein Expression** | **n=67** | **Protein Expression of Normal Adjacent Tissue (mean±SD)** | **Protein Expression of Cancer Tissue (mean±SD)** | **p** |
| PTEN | 67 | 1.293±0.722 | 1.297±0.738 | 0.938 |
| PDCD4 | 67 | 1.331±0.889 | 1.235±1.004 | 0.296 |
when compared to the cancer tissue (p=0.938). For PDCD4 protein expression on the other hand, the normal tissue specimen showed a relatively higher expression compared to the tumour counterpart (p=0.296). This suggested that in the cancer tissues, there was slight downregulation of the protein's expression of both PTEN and PDCD4 compared to the normal tissues, a result that was consistent with that of the mRNA expression level.

The Correlational Expression of miR-21, PTEN and PDCD4 Among BC Patients

To investigate the correlational expression of this study’s target genes; miR-21, PTEN and PDCD4 among 67 BC patients, Spearman's rho was utilised to deduce if the gene expression of miR-21 with PTEN and miR-21 with PDCD4 were correlated. This correlation between the two variables is illustrated in Table 4. The relationship (or correlation) between the two variables is denoted by the letter r (Spearman's rho value) and quantified with a number, which varies between -1 and +1.\[57\] If the value is close to zero, it is said to have a negligible or a lack of correlation. Meanwhile if the value is close to one, the variables is said to have a strong correlation. Additionally, the sign of the r shows the direction of the correlation. A positive correlation is identified by a positive value while a negative correlation is indicated by a negative value.\[57, 58\] To visualise the trend of correlation between gene expression, a scatterplot graph was plotted between PTEN against miR-21 (Fig. 3A) and PDCD4 against miR-21 (Fig. 3B).

Based on Spearman’s rho analysis for the level of correlation between PTEN against miR-21 as well as PDCD4 against miR-21, there was a lack of correlation between the two pairs (Table 4). The \( r_s \) values were a mere \( r_s = -0.020 \) and \( r_s = 0.037 \), respectively. As the Spearman's rho coefficient value is close to zero, this value is too low to indicate the presence of a correlation, which consequently did not reach significance (p=0.875 and p=0.767, respectively).

Discussion

Significant progress has been made in the 21st century when it comes to diagnosis and treatment of human malignancies. In this report, we’ve shown that miR-21 expression was significantly higher in BC tissues compared to its normal tissue counterpart (p<0.001). These results are further reinforced with recent studies which also reflected the same outcome between these two tissue types when utilising the relative quantification method.\[59-64\] The regulation of miR-21 expression and its targeting of PTEN is complex and involves many factors, including transcription factors, epigenetic modifications, and signalling pathways.\[65-67\] As of recent, studies that analysed the expression patterns of PTEN among breast specimens and its gene expression correlation with miR-21 have been conflicting.\[36\] In this study, PTEN was significantly expressed in the normal adjacent tissue compared to the breast tumour tissue. Five other studies compiled in a meta-analysis also compared PTEN expression in breast tumour tissues and its matched normal tissues and unanimously showed a significantly higher expression of PTEN in the matched normal tissues compared to the tumour counterpart.\[68-72\] In this study, PTEN and miR-21 was also investigated for its correlation in gene expression. Based on the Spearman’s rho, PTEN and miR-21 showed a lack of correlation, with no significant difference in expression. Such results could be due to this study’s low sample population along with the inclusion of NAC treated patients that could have plausible treatment-induced changes to gene expression profiles. This assumption could be justified based on similar previ-

Table 4. PTEN and PDCD4 Genes Expression Correlation in Breast Cancer Tissues

<table>
<thead>
<tr>
<th>Gene Expression</th>
<th>n=67</th>
<th>Spearman’s rho Correlation Coefficient</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTEN against miR-21</td>
<td>67</td>
<td>-0.020</td>
<td>0.875</td>
</tr>
<tr>
<td>PDCD4 against miR-21</td>
<td>67</td>
<td>-0.037</td>
<td>0.767</td>
</tr>
</tbody>
</table>

Figure 3. Spearman’s rho scatterplot of (a) PTEN against miR-21 gene expression and (b) PDCD4 against miR-21 gene expression.
ous studies that showed a correlation in gene expression between miR-21 and PTEN, which excluded BC patients that had undergone treatment.[75] Moreover, miR-21 expression was observed to be highly expressed in the breast tumour tissues despite the patients have undergone several cycles of chemotherapy. This trend can also be observed in a study that analysed the correlative expression of miR-21 and PTEN among 120 BC patients did not reach a significant correlation coefficient. The nature of the collected breast specimens, whether the patients have undergone BC treatment or not was not disclosed.[38]

Despite the novelty of PDCD4 and its regulatory effects in preventing carcinogenesis, many open questions persist regarding the molecular basis of its functionality when there is an overexpression of miR-21 in BC.[73] This study’s results showed no significance in expression of both tissue types, although upregulated in the normal adjacent tissue. Meanwhile, there was also negligible correlation of miR-21 and PDCD4 gene expression. Abdulhussain et al. (2019) had a significant inverse correlation between miR-21 and PDCD4 expression in 60 matched BC tissue specimens (p<0.001, r=-0.59).[74] The aforementioned study, however derived their BC specimens from patients who have not undergone any BC treatment while this current study included BC specimens from treated BC patients, which could potentially be the cause of the absence of significance of PDCD4’s expression in tissue and correlational expression. A similar BC study also had a significant inverse correlation between miR-21 and PDCD4 expression in breast tumour and normal adjacent tissue among 20 BC patients who have not undergone BC treatment.[75] Conversely, the aforementioned study also investigated the genetic profiles of treatment resistant BC cell lines and discovered the overexpression of miR-21 while PDCD4 mRNA expression remain unchanged.[75]

At present, there is very limited information that is available regarding the effect of chemotherapy on miR-21 expression in BC and its correlation with clinical improvement. Sukhija et al. (2023) collected blood samples from BC patients before and after receiving chemotherapy and compared the respective expression of miR-21. After NAC, the expression of miR-21 was significantly increased by 5.65-fold. They have deduced that NAC causes clinical improvement in BC patients but is not correlated with miR-21 expression despite being significantly increased after chemotherapy.[76] Additionally, this study’s findings were congruent to a previous study that investigated the same variables of gene expression correlation and protein expression of the tumour suppressors in matched BC tissues. There was a significant expresional difference of miR-21 where it was upregulated in the tumour tissues compared to its normal counterpart. However, there was no significance in gene expression correlation between miR-21 and PDCD4, while PTEN and PDCD4 proteins had no significant difference of its expression in matched BC tissues.[77]

After conducting western blot procedure for 67 pairs of tissues for protein detection and quantification of PTEN and PDCD4, no significance was found between the two tissue types and among both proteins although the normal adjacent tissues showed a slight increase of both tumour suppressor proteins compared to the cancer tissue counterpart. Both studies conducted by Kechagioglou et al. (2014) and Qi et al. (2009) have failed to detect loss of PTEN expression in invasive and in situ ductal breast carcinoma.[78] The depletion of PTEN functionality has been attributed to inactivation of PTEN protein via post-translational alterations.[80, 81] The phosphorylation of PTEN in specific residues transposes the molecule from an open into a closed conformation thus inactivating the molecule.[82] Therefore, a plausible explanation for this study’s PTEN protein expression could be related to Kechagioglou et al. (2014), where the expression of phosphorylated PTEN is more pronounced among the patient cohort with breast cancer compared to their healthy controls. This suggests that despite the presence of gene expression, phosphorylation can be a pathway of protein inactivation in breast cancer.[78] Not only that, while such phosphorylated modifications occur, this can also affect PTEN localisation to the plasma membrane which limits its interaction with PIP3.[83]

Other than the possibility of phosphorylated PTEN that conceived such results in this study, recent studies have proven that PTEN has three alternative translation isoforms; PTENα, PTENβ and PTENε, that are originated from the same mRNA as canonical PTEN.[84-86] Interestingly, in contrast with canonical PTEN and its tumour suppressive role, PTENα and PTENβ expression promote tumorigenesis.[87] In a 2019 study that investigated the expression of canonical PTEN and its isoforms in liver cancer tissues in comparison with the normal tissues, it was discovered that the expression trend of PTENα and PTENβ were not always consistent as canonical PTEN since the levels of PTENα and PTENβ proteins remain unchanged, or an increase was observed in tumour tissues with decreased canonical PTEN as compared to the normal adjacent tissues. The same variables were also tested on xenograft models which had consistent results with the liver patient cohort.[87] Frankel et al. (2008) also investigated PTEN-miR-21 interaction in breast cancer cells by transfecting MCF-7 cells with a miR-21 precursor, a miR-21 inhibitor, and appropriate controls. Interestingly, these treatments caused only subtle changes in PTEN protein levels which suggests that cell and tissue type specific differences may result in different functional miR-21 targets.[88]
Typically, PDCD4 protein are down-regulated in cancer cells, however there has been an increasing amount of cancer patients with upregulated PDCD4 protein originated from tumours that showed poor survival.\textsuperscript{[89]} A study was done with MCF-7 breast cancer cell line which demonstrated that the methylation of PDCD4 had caused inactivation and upregulation of PDCD4 protein which was associated with tumour cell growth and viability.\textsuperscript{[89]} When it comes to PDCD4 with its mRNA and protein expression, this disparity was identified in a lung cancer study by comparing its expression in both lung tumour and normal adjacent tissue.\textsuperscript{[90]} Based on the results derived from the lung tissues, PDCD4 protein was observed to increase in expression in the lung tumour tissues compared to the non-tumour counterpart. Additionally, PDCD4 mRNA and protein changes in expression was not in parallel in most of the tissue pairs and this also meant a significant increase of protein levels was observed in tumours where no changes in PDCD4 mRNA level were detected or suppressed.\textsuperscript{[90]}

The multi-ethnic composition of Malaysian society offers a population in which comparative studies of genetics may be performed. Our results revealed that there was no significant difference in the expression of miR-21 between BC patients from each of Malaysia's three main ethnic groups (Malay, Indian and Chinese). This consistency among ethnicities is similarly seen among other cancer types, such as oral squamous cell carcinomas\textsuperscript{[91]} and lung adenocarcinoma.\textsuperscript{[92]} Furthermore, this consistency is not limited to Asian ethnicities, as one meta-analysis of miR-21 expression in multiple cancer types demonstrated no correlational significance among Asian, Caucasian and African American populations.\textsuperscript{[93]} This evidence supports our results. Moreover, another rationale of this study's results is the ethnic distribution in the patient cohort, which consisted of 53 Malay patients, 7 Chinese and 7 Indian patients, which could have skewed the expression of miR-21 due to the evident clustering of the Malay ethnicity in the patient cohort. It was deduced in this study that miR-21 expression had no significant correlation with the 4 patient age groups. Despite this study consisting of only 67 patients, other studies conducted that carried out similar correlative studies discovered that there was no significance between age groups and miR-21 expression.\textsuperscript{[94, 95]}

Even with a larger patient cohort of 252 participating BC patients, it did not demonstrate a correlation between age groups with the oncogenic miR-21.\textsuperscript{[90]} Therefore, based on this study's results and previous literature which consisted of larger patient cohort, it can be presumed that miR-21's clinical significance can be suitable to be evaluated further in patients of all ethnicities and age groups.

In this study, miR-21 was upregulated in patients with BC, regardless of previous exposure to chemotherapy, which consequently, showed no significant difference. However, chemotherapy naive patients still presented higher relative fold change values than the chemotherapy treated patients. This finding is aligned with the report of Sales et al. (2022) who assessed the expression of miR-21 and reported that miR-21 expression did not show any significant difference between the chemotherapy-treated and chemotherapy naive patients.\textsuperscript{[97]} These findings reinforce a possible downregulation of miR-21 following an optimal response to chemotherapy. The prognostic potential of circulating miR-21 had also been previously investigated where a significant proportion of BC patients who had undergone neoadjuvant chemotherapy had an increased expression of exosomal miR-21 that eventually develop metastatic disease.\textsuperscript{[98]}

The majority of current studies of the role of microRNA have been coordinated regardless of the tumour's molecular subtype. This study's results revealed that the expression of miR-21 was upregulated in all subtypes but did not reach a significant difference, which could be attributed by the final sample size (67 patients). However, other reports with higher number of BC patients confirmed that miR-21 expression was similar in different BC subtypes which did not exhibit a clear discrimination between the subtypes, thus reinforcing our results.\textsuperscript{[97, 99, 100]} Additionally, luminal breast cancers are known to be a result of somatic mutations\textsuperscript{[101]} while, triple negative breast cancers are due to germline mutations with 80% of cases that arise from the BRCA1 or BRCA2 mutation.\textsuperscript{[102]} As this study's total luminal A and B BC subtype (46 patients) is evidently more than the total TNBC subtype (12 patients), this could also be the source for the absence of discrimination between miR-21 expression and the subtypes as the distribution of the subtypes are heavily skewed. Evidently, BC staging and subtype determination is dependent on the expression of hormone receptors, including oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in tumours, which also defines prognosis and aid in deciphering treatment options.\textsuperscript{[103]} Thus, it is clear that gene expression defines BC and therefore, the possibility of miRNA expression to display subtype specificity is presumed to exist.\textsuperscript{[104, 105]} A meta-analysis published in 2022 compiled a list of distinct miRNAs that correspond to every BC subtype.\textsuperscript{[104]} Despite the extensive list of biomarkers proven to be molecularly specific for each subtype, the common denominator in this metanalysis depicts too many miRNAs to allow testing for specific subtypes. Therefore, having a sole miRNA such as miR-21 that is constantly proven in its upregulation in BC would be more convenient. To aid the issue of specificity of miR-21 in BC, the development of an enzyme-powered
miRNA discriminator (T7 Exonuclease powered digestion) was designed in a 2023 study to distinguish BC cells from normal cells. Moreover, this enzyme could further identify subtype features using miR-21 as a universal biomarker and miR-210 to identify triple negative subtype features. Interestingly, this method was successful in distinguishing BC cell lines respective to the subtypes; MCF-7 (ER positive), BT-474 (HER-2 positive), MDA-MB-231 (triple negative) with MCF-10A as a control. miR-21 levels were found to have a constant increase in the BC cell lines according to the increasing severity of each subtype using the T7 Exo powered miRNA in relative to the normal cell line.[106] Ultimately, future works of defining oncomiR expression with the use of innovative techniques could bring us a step closer to a reliable universal biomarker.

When it comes to the Malaysian demographic and its influence on miR-21 expression, it is evident that there is no clear correlation between age groups, ethnicities, subtypes and treatment received. Therefore, we can say that based on this study’s patient cohort, miR-21’s gene expression is independent, as it is upregulated when a patient has BC. Nevertheless, significant differences were found between miR-21 expression and the specimen type (normal adjacent tissue and breast cancer tissue), which reflects other similar studies with the same results obtained when utilising the 2−ΔΔCT method where patients diagnosed with BC had a higher miR-21 fold change compared to the normal tissues (p<0.001). Moreover, significance was also found in PTEN’s expression within the specimen types, where PTEN was significantly upregulated in the normal adjacent tissues compared to the breast tumours (p=0.010). PDCD4’s expression was also upregulated in the normal adjacent tissues and downregulated in breast tumours, although no significant difference was found (p=0.451). However, there was a lack in correlation, based on the Spearman’s rho analysis between gene expression of miR-21 against PTEN and miR-21 against PDCD4 which showed: rs=−0.020, p=0.875 and rs=−0.037, p=0.767, respectively. PTEN and PDCD4 protein expression in this study showed little difference of the tumour suppressor proteins in both tissue types. This could be theorised to occur due to post-translational modifications such as phosphorylation of the proteins or the existence of isomers from a single mRNA which allowed the proteins to be expressed but is instead non-functional and therefore prompted tumourigenesis. Despite the absence of significance in most demographical factors and groups in this study, therefore, we can agree that miR-21 has a notable presence in BC and is a suitable biomarker to be evaluated further in patients of all ethnicity and age groups. Additionally, miR-21 should further be studied for its possibility as a circulating biomarker.

Disclosures
Ethics Committee Approval: This present study involves the use of human subjects which include tissue specimens. The human ethics approval obtained for this project to collect the patients derived tissue specimens via the University Putra Malaysia institutional ethics review board and Ministry of Health Medical Research Ethics Committee (MREC) prior to the commencement of the study. The ethics approval code is NMRR-21-246-58614 (IIR).

Peer-review: Externally peer-reviewed.
Conflict of Interest: None declared.

Authorship Contributions: SRW carried out all experiments, specimen and patient information collection, participated in all the statistical analysis and drafted the manuscript. SHL supervised, conceived, reviewed, revised, drafted and edited the manuscript. AB assisted in the tissue specimen collection. CPP, TMIM, and GLT co-supervised and reviewed the manuscript. SN assisted with the statistical analysis. All authors read and approved the final manuscript.

Availability of data and materials: The datasets used and/or analysed in the current study are available from the corresponding author upon reasonable request.

Funding: This study was supported by Fundamental Research Grant Scheme (FRGS/1/2020/STG03/TAYLOR/03/1), Malaysian Ministry of Higher Education and Universiti Putra Malaysia Grant 2020 (GP-IPM/2020/9694400).

Acknowledgements: We would like to express our gratitude to Dr. Lavannya A/P Rangasparan and Dr. Vimal A/L Chandran who diligently recruited and ethically attained the tissues from willing breast cancer patients for this study. Our sincerest thanks to the brave women who selflessly donated their tissues used in this project.

References


